Kala Bio Inc KALA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
-
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
-
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
-
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Trading Information
- Previous Close Price
- $0.19
- Day Range
- $0.18–0.20
- 52-Week Range
- $0.11–95.50
- Bid/Ask
- $0.18 / $0.20
- Shares Outstanding
- 19.34M
- Market Cap
- $3.67M
- Volume/Avg
- 287,571 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.kalarx.com
Valuation
|
Metric
|
KALA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KALA
|
|---|---|
Quick Ratio | 4.84 |
Current Ratio | 6.88 |
Interest Coverage | −8.57 |
Quick Ratio
KALA
Profitability
|
Metric
|
KALA
|
|---|---|
Return on Assets (Normalized) | −93.39% |
Return on Equity (Normalized) | −584.71% |
Return on Invested Capital (Normalized) | −112.54% |
Return on Assets
KALA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<^L%DR | LOCK|$H#QV | $127B | |||
| Moderna Inc
MRNA
| LOCK|vjd@#XP | LOCK|TKz | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|WsFh@! | LOCK|?G?$Q | $81B | |||
| argenx SE ADR
ARGX
| LOCK|<!WV!Cs | LOCK|v$# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|yd!j!w | LOCK|Xbf | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|HgrCm?M | LOCK|?>>W$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x@>#^x# | LOCK|FB!j% | $27B | |||
| Incyte Corp
INCY
| LOCK|Wq^#w&K | LOCK|!# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qD>w&h | LOCK|^M | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|SWFfll | LOCK|#R | $14B |
United States